Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the main study group (cases):
- Female patients who are 18 years of age or older at the time of joining the study (the original diagnosis may have happened before age 18)
- People with a diagnosis of a larger prolactin-producing pituitary tumour (called a macroadenoma) made between January 2013 and December 2023
- People whose diagnosis was confirmed by a specific type of brain scan (MRI with contrast dye) showing a tumour larger than 10 mm on at least one measurement, along with certain blood prolactin hormone levels, or surgical confirmation
- People who have had at least part of their follow-up care carried out at the Endocrinology Department of Hospices Civils de Lyon (HCL)
- People who are able to understand the study and agree to take part
For the comparison group (controls):
- Female patients who are 18 years of age or older at the time of joining the study (the original diagnosis may have happened before age 18)
- People with a diagnosis of a smaller prolactin-producing pituitary tumour (called a microadenoma) made between January 2013 and December 2023
- People whose diagnosis was confirmed by a specific type of brain scan (MRI with contrast dye) showing a tumour smaller than 10 mm on all measurements, along with elevated blood prolactin levels measured under neutral conditions
- People who have had at least part of their follow-up care carried out at the Endocrinology Department of Hôpital Louis Pradel
- People who are able to understand the study and agree to take part
Who may not be able to join:
For the main study group (cases):
- People whose large pituitary tumour does not produce prolactin
- People with a history of high prolactin levels or a pituitary abnormality recorded before 2013 that was never directly confirmed as a prolactin-producing tumour
- People with a known genetic condition or inherited syndrome that increases the likelihood of developing a prolactin-producing tumour
For the comparison group (controls):
- People whose small pituitary tumour does not produce prolactin
- People whose diagnosis of a pituitary tumour is still uncertain and who are currently on a trial treatment to help clarify the diagnosis
- People with high prolactin levels in the blood but no confirmed pituitary tumour found on imaging
- People with a history of high prolactin levels or a pituitary abnormality recorded before 2013 that was never directly confirmed as a prolactin-producing tumour
- People with a known genetic condition or inherited syndrome that increases the likelihood of developing a prolactin-producing tumour
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 04 27 85 66 66
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
number of patients exposed to combined estrogen-progestin contraception; number of patients exposed to menopausal hormone therapy; number of patients exposed to progestin-only treatment; number of patients exposed to Ovarian Stimulation; Age at First Use of Hormonal Contraception; Age at Menarche; Age at Menopause; Age at First Live Birth; Nulliparity; Number of Pregnancies Carried to Viability; Exposure to Breastfeeding defined as the total cumulative duration of breastfeeding across all pregnancies, expressed in months. • None: 0-1 month • Moderate: 1-12 months • High: >12 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.